Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the t…
$0.05-8.65%
报价 2026-11-06
市值
$1.2M
EV
$179.8M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -99.5%
$0.05$10.67
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| KPTIKaryopharm Therapeutics Inc. | $1.2M | -8.7% | -6.3% | 95.9% | – | – | – | |
| XFORX4 Pharmaceuticals, Inc. | $315.3M | +3.6% | -73.4% | 81.2% | – | – | – | |
| TELOTelomir Pharmaceuticals, Inc. Common Stock | $52.3M | -9.0% | -99.9% | 0% | – | – | – | |
| INMBINmune Bio, Inc. | $31.4M | -3.8% | 0.0% | 0% | – | – | – | |
| CVMCEL-SCI Corporation | $25.5M | +5.8% | +304.3% | 0% | – | – | – | |
| ALGSAligos Therapeutics, Inc. | $25.4M | -9.8% | +528.0% | 99.2% | – | – | – | |
| SNTISenti Biosciences, Inc. | $5M | -2.7% | +150.0% | -2,736.4% | – | – | – | |
| MDCXMedicus Pharma Ltd. | $2.7M | +2.2% | – | 0% | – | – | – | |
| 同行中位数 | – | – | +75.0% | 0% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。